HK1138277A1 - Prophylactic and/or therapeutic agent for hyperlipemia - Google Patents

Prophylactic and/or therapeutic agent for hyperlipemia

Info

Publication number
HK1138277A1
HK1138277A1 HK10104519.2A HK10104519A HK1138277A1 HK 1138277 A1 HK1138277 A1 HK 1138277A1 HK 10104519 A HK10104519 A HK 10104519A HK 1138277 A1 HK1138277 A1 HK 1138277A1
Authority
HK
Hong Kong
Prior art keywords
solvate
salt
prophylactic
hyperlipemia
therapeutic agent
Prior art date
Application number
HK10104519.2A
Other languages
English (en)
Inventor
Toshiaki Takizawa
Noriyuki Inoue
Katsutoshi Miyosawa
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of HK1138277A1 publication Critical patent/HK1138277A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK10104519.2A 2007-03-29 2010-05-10 Prophylactic and/or therapeutic agent for hyperlipemia HK1138277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007087081 2007-03-29
PCT/JP2008/000788 WO2008120472A1 (fr) 2007-03-29 2008-03-28 Agent prophylactique et/ou thérapeutique contre l'hyperlipémie

Publications (1)

Publication Number Publication Date
HK1138277A1 true HK1138277A1 (en) 2010-08-20

Family

ID=39808058

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10104519.2A HK1138277A1 (en) 2007-03-29 2010-05-10 Prophylactic and/or therapeutic agent for hyperlipemia

Country Status (12)

Country Link
US (1) US8426455B2 (fr)
EP (2) EP2433932A1 (fr)
JP (1) JP5275975B2 (fr)
KR (1) KR101420319B1 (fr)
CN (1) CN101627021B (fr)
AT (1) ATE549323T1 (fr)
CA (1) CA2680407C (fr)
ES (1) ES2380752T3 (fr)
HK (1) HK1138277A1 (fr)
PT (1) PT2141155E (fr)
TW (1) TWI407955B (fr)
WO (1) WO2008120472A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484361B1 (fr) * 2009-09-28 2015-11-11 Kowa Company, Ltd. Agent pour réduire le poids de graisse viscérale
CN102977085B (zh) * 2011-10-27 2015-07-29 四川大学 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途
CA2901650C (fr) 2012-09-27 2021-05-04 Kowa Company, Ltd. Agent therapeutique pour la dyslipidemie
AU2014312931B2 (en) * 2013-08-28 2019-09-19 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
PT3275438T (pt) 2016-07-29 2021-01-25 Kowa Co Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual
EP3646865A4 (fr) * 2017-06-30 2021-03-17 Kowa Company, Ltd. Médicament
EP3646866A4 (fr) * 2017-06-30 2021-03-24 Kowa Company, Ltd. Préparation pharmaceutique
EP3646863B1 (fr) * 2017-06-30 2024-01-03 Kowa Company, Ltd. Composition pharmaceutique
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20210290598A1 (en) * 2018-05-08 2021-09-23 National University Corporation Okayama University Medicament useful for cardiovascular disease
EP3903780A4 (fr) * 2018-12-27 2023-01-18 Kowa Company, Ltd. Produit médicinal
KR102289381B1 (ko) 2020-03-17 2021-08-17 주식회사 대웅테라퓨틱스 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
DE19858789A1 (de) 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
KR20020005662A (ko) 1999-04-09 2002-01-17 기따자또 이찌로 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약
CA2456732C (fr) 2001-08-07 2012-10-30 Galephar M/F Composition pharmaceutique orale contenant une combinaison de ppar.alpha. et d'un inhibiteur de l'hmg-coa reductase
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
AU2003225027A1 (en) * 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist
AU2004270538C1 (en) * 2003-09-03 2010-01-14 Kowa Co., Ltd PPAR-activating compound and pharmaceutical composition containing same
CA2555316A1 (fr) 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. Composition pharmaceutique combinant divers ingredients
PL1852426T3 (pl) * 2005-02-23 2014-04-30 Kowa Co Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego
JPWO2006090756A1 (ja) * 2005-02-25 2008-07-24 杏林製薬株式会社 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用
AR054368A1 (es) 2005-06-01 2007-06-20 Takeda Pharmaceutical Metodo para tratar hiperlipidemia

Also Published As

Publication number Publication date
EP2141155A1 (fr) 2010-01-06
CA2680407C (fr) 2015-04-21
US20100069433A1 (en) 2010-03-18
EP2141155A4 (fr) 2010-05-19
TW200838510A (en) 2008-10-01
ATE549323T1 (de) 2012-03-15
CA2680407A1 (fr) 2008-10-09
CN101627021A (zh) 2010-01-13
EP2141155B1 (fr) 2012-03-14
EP2433932A1 (fr) 2012-03-28
WO2008120472A1 (fr) 2008-10-09
KR101420319B1 (ko) 2014-07-16
CN101627021B (zh) 2012-11-28
TWI407955B (zh) 2013-09-11
JP5275975B2 (ja) 2013-08-28
KR20090129994A (ko) 2009-12-17
US8426455B2 (en) 2013-04-23
JPWO2008120472A1 (ja) 2010-07-15
PT2141155E (pt) 2012-05-23
ES2380752T3 (es) 2012-05-18

Similar Documents

Publication Publication Date Title
HK1138277A1 (en) Prophylactic and/or therapeutic agent for hyperlipemia
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
CL2007003192A1 (es) Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l'obesite, de maladies associees a l'insuline et de l'hypercholesterolemie
CL2012001133A1 (es) Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.
PT1789403E (pt) Derivados de n-(fenil-oxazol-4-ilmetoximetil)-ciclo-hexilsuccinamida e compostos relacionados como ligandos dos ppar (receptores activados de proliferadores de peroxisomas) para o tratamento da hiperlipidemia e diabetes
MY148125A (en) Compounds
EP2070540A4 (fr) Composition de médicament pour le traitement du diabète de type 2 et sa néopathie chronique
EP2137175A4 (fr) Nouveau composé à base de phénanthrènequinone et composition pharmaceutique contenant ce dernier utilisé pour le traitement ou la prévention du syndrome métabolique impliquant des maladies
BRPI0911197A2 (pt) composto, ativador de receptor ativado pelo proliferador de peroxissoma, e, medicamento para o tratamento e /ou profilaxia de uma doença.
MX2010001352A (es) Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares.
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
WO2009047565A3 (fr) Composition 064
TW200800954A (en) Novel crystal modifications
EA200701615A1 (ru) Новые лекарственные средства для лечения заболеваний дыхательных путей
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
WO2007047431A3 (fr) Composes d'aryle substitues par du sulfonyl en tant que modulateurs de recepteurs actives par les inducteurs de la proliferation des peroxysomes
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
WO2011098799A3 (fr) Traitement de maladie respiratoire